More MS news articles for February 2004

Celltech in autoimmune drug deal with Biogen Idec

http://www.forbes.com/home_europe/newswire/2004/02/05/rtr1243099.html

Feb 5, 2004
Mark Potter
Reuters

Britain's biggest biotech firm Celltech said on Thursday it had entered into a collaboration to research, develop and commercialise treatments for autoimmune diseases with U.S. peer Biogen Idec.

Celltech said it would be responsible for identifying and engineering new antibodies to treat diseases such as rheumatoid arthritis and multiple sclerosis, and will pay all development costs until the end of Phase I clinical trials.

Biogen Idec will then have the option to co-invest in the ongoing development of the products.